Page 4 - Neeraj Agarwal News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Roche and Exelis/Ipsen s drug combination shows promise in phase 3 prostate cancer study

Roche and Exelis/Ipsen s drug combination shows promise in phase 3 prostate cancer study
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

United statesExelixis ipsen cabometyxTecentriq cabometyxNeeraj agarwalRoche tecentriqUniversity of utahAmerican cancer societyAmerican cancerAmerican societyClinical oncology genitourinary cancers symposium

Atezolizumab Plus Cabozantinib Improves PFS Over Novel Hormonal Therapy in mCRPC

A significant progression-free survival improvement was achieved with cabozantinib plus atezolizumab vs second-line novel hormonal therapy in mCRPC.

Neeraj agarwalGlobal health statusUniversity of utahEuropean organization for researchGenitourinary oncology gu programHuntsman cancer instituteGenitourinary oncologyInvestigational therapeuticsEuropean organizationCancer qualityCabozantinib plus atezolizumabMetastatic castration resistant prostate cancer2024 genitourinary cancers symposiumPhase 3 contact 02 trial

Cabometyx, Tecentriq stave off prostate cancer progression as Exelixis joins Novartis on FDA s wait list

Cabometyx, Tecentriq stave off prostate cancer progression as Exelixis joins Novartis on FDA s wait list
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

United statesRoche tecentriqAmy petersonExelixi cabometyxNeeraj agarwalUniversity of utahAmerican society of clinical oncologyClinical oncologyGenitourinary cancersFierce pharma

Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024

– Cabozantinib in combination with atezolizumab reduced the risk of disease progression or death by 35% in patients with metastatic castration-resistant prostate cancer – – Findings to be.

United statesNeeraj agarwalAmy petersonAmerican cancer societyEuropean unionUniversity of utahExchange commissionProduct development medical affairsTakeda pharmaceutical company limitedClinical research at huntsman cancer instituteExelixis incDrug administrationAmerican society of clinical oncologyOral abstract sessionProstate cancerAmerican society

Cabometyx, Tecentriq Combo Improves Time to Progression in mCRPC

Cabometyx plus Tecentriq led to improved progression-free survival compared with novel hormonal therapy in patients with metastatic castration-resistant prostate cancer.

Neeraj agarwalCabometyx tecentriqGlobal health statusEuropean organization for researchUniversity of utahGenitourinary oncology gu programHuntsman cancer instituteGenitourinary oncologyInvestigational therapeuticsEuropean organizationCancer qualityGlobal healthProstate cancerMetastatic castration resistant prostate cancerAsco gu24